Valuation: Foresee Pharmaceuticals Co., Ltd.

Market Cap 12.92B 399M 351M 327M 300M 563M 38.57B 573M 3.88B 1.51B 18.9B 1.5B 1.47B 65.43B P/E 2024
-9.84x
P/E 2025 -14.1x
Enterprise Value 12.67B 392M 344M 320M 294M 552M 37.83B 562M 3.81B 1.48B 18.54B 1.47B 1.44B 64.17B EV / Sales 2024
26x
EV / Sales 2025 28.9x
Free-Float
47.69%
Yield 2024 *
-
Yield 2025 -
07-09 Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Brian J. Groch to Chief Commercial Officer, Effective July 1, 2026 CI
06-08 Foresee Pharmaceuticals Oral ALDH2 Activator Mirivadelgat Enters Clinical Testing in Parkinson's Disease in the SLEIPNIR Phase 2A Platform Trial CI
05-27 Foresee Pharmaceuticals Completes Casppian Phase 3 Study and Confirms Topline Results for FP-001 42 Mg in Central Precocious Puberty CI
05-14 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-13 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-06 Foresee Pharmaceuticals Announces Positive ChHMP Opinion Recommending Approval Of CAMCEVI 21 Mg 3-Month Strength In European Union CI
02-04 Foresee Pharmaceuticals Co., Ltd. Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty CI
12-24 Foresee Pharmaceuticals Announces Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust Lh Suppression with 6-Month Dosing Interval of Leuprolide Mesylate CI
11-13 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
29/08/25 Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI ETM for the Treatment of Advanced Prostate Cancer CI
12/08/25 Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
31/07/25 Foresee Pharmaceuticals Co., Ltd. announced that it expects to receive TWD 400 million in funding CI
17/06/25 Foresee Completes Phase 3 CASPPIAN Trial Enrollment For Central Precocious Puberty RE
1 day-1.20%
1 week+2.63%
Current month+1.49%
1 month+3.67%
3 months+1.61%
6 months+2.12%
Current year+1.74%
1 week 79
Extreme 79
83.3
1 month 77.9
Extreme 77.9
86.6
Current year 75.1
Extreme 75.1
88.3
1 year 71.9
Extreme 71.9
93.7
3 years 57.7
Extreme 57.7
107.5
5 years 57.7
Extreme 57.7
141
10 years 35.1
Extreme 35.1
141
Manager TitleAgeSince
Chief Executive Officer - 08/02/2013
Chief Tech/Sci/R&D Officer - 09/07/2015
Director of Finance/CFO 58 07/10/2019
Director TitleAgeSince
Director/Board Member - 10/01/2013
Director/Board Member - 10/01/2013
Director/Board Member 75 03/08/2015
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%+2.63%+12.64%-2.38% 399M
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average +0.08%+1.04%+50.27%+95.18% 24.57B
Weighted average by Cap. +0.48%+0.92%+75.21%+136.40%

Financials

2024 2025
Net sales 419M 12.95M 11.38M 10.58M 9.71M 18.23M 1.25B 18.57M 126M 49.07M 613M 48.6M 47.55M 2.12B 431M 13.34M 11.73M 10.9M 10M 18.78M 1.29B 19.13M 130M 50.55M 631M 50.06M 48.98M 2.18B
Net income -1.08B -33.43M -29.39M -27.33M -25.08M -47.08M -3.23B -47.95M -325M -127M -1.58B -125M -123M -5.48B -883M -27.31M -24.01M -22.32M -20.49M -38.46M -2.64B -39.17M -265M -104M -1.29B -103M -100M -4.47B
Net Debt -1.11B -34.23M -30.1M -27.98M -25.68M -48.21M -3.31B -49.09M -332M -130M -1.62B -128M -126M -5.61B -248M -7.66M -6.74M -6.26M -5.75M -10.79M -740M -10.99M -74.42M -29.04M -363M -28.76M -28.14M -1.25B
Logo Foresee Pharmaceuticals Co., Ltd.
Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.
Employees
-
Date Price Change Volume
24/07/26 NT$82.00 -1.20% 71,048
23/07/26 NT$83.00 0.00% 81,183
22/07/26 NT$83.00 +0.97% 165,207
21/07/26 NT$82.20 +3.14% 204,505
20/07/26 NT$79.70 -0.25% 78,784
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
82.00TWD
Average target price
153.00TWD
Spread / Average Target
+86.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 6576 Stock